Aurobindo Pharma completes $250 million acquisition of Trade Brains group-based Lannett Company. Synopsis: Aurobindo Pharma Limited has completed the acquisition of Lannett Company through its US subsidiary, strengthening its presence in the American pharma market. The deal expands manufacturing capacity, product reach, and supports Aurobindo's long-term strategy to grow deeper in the US healthcare sector. Aurobindo Pharma USA Inc. (APUSA), a wholly owned subsidiary of Aurobindo Pharma Limited, has successfully completed its acquisition of Lannett Company, Inc. from Lannett Seller Holdco, Inc. Following clearance from the U.S. Federal Trade Commission (FTC) on June 18, 2026, the transaction became operationally effective on June 29, 2026. Under the Aurobindo group, the entity will now operate as Lannett Company LLC. According to the company's official exchange filing on June 30, 2026, the integration process has officially commenced. To secure FTC approval and maintain retail market competition, Aurobindo agreed to a consent order requiring the divestiture of four generic drug lines (including Mycophenolate Mofetil and Pilocarpine) to Quagen Pharmaceuticals. Despite these minor product divestitures, management explicitly noted that the transaction is expected to be immediately accretive to the Aurobindo Group's earnings per share (EPS) while onboarding over 400 Lannett employees. Shares of Aurobindo Pharma Limited, with a market capitalisation of Rs. 90,023.63 crore, are trading at Rs. 1,566.30, up 1.21% from its previous closing price. The stock touched an intraday high of Rs. 1,578.00 and a low of Rs. 1,547.50. It is currently trading at a P/E ratio of 25.43. The acquisition immediately adds Lannett's revenues, assets, manufacturing infrastructure, and distribution network into Aurobindo's consolidated business. While exact transaction terms were previously disclosed at $250 million, the long-term value lies beyond immediate revenue contribution. Unlike organic expansion, where new drug approvals through the ANDA pipeline can take years, this deal gives Aurobindo immediate access to an existing US product portfolio and customer base. In the near term, integration costs related to workforce transition, system alignment, and operational restructuring may create temporary margin pressure before synergies begin to reflect in earnings. Strategic interpretation. This acquisition represents more than just geographical expansion. It strengthens Aurobindo's push toward becoming a deeper US-based pharmaceutical manufacturer rather than simply an exporter. You May Like A major advantage lies in product portfolio expansion. Lannett provides Aurobindo with a dominant foothold in specialized generic segments like complex, non-opioid controlled substances (such as ADHD medications), which feature high regulatory barriers to entry. Crucially, the deal hands Aurobindo an established, massive 4-billion-dose annual capacity manufacturing facility in Seymour, Indiana, dramatically amplifying its local manufacturing presence on American soil. The second major benefit is vertical integration efficiency. Aurobindo is one of India's largest producers of Active Pharmaceutical Ingredients (APIs). By supplying its own APIs directly into Lannett's US manufacturing facilities, the company can reduce dependence on third-party procurement and improve gross margins across acquired product lines over the next 12 - 18 months. The deal also helps reduce regulatory and geopolitical risk. With growing emphasis in the US on domestic pharmaceutical manufacturing and "Made in America" healthcare supply chains, having local production capacity protects Aurobindo from potential import tariffs, supply disruptions, and policy changes while improving eligibility for government procurement contracts for essential medicines. Discover more Digital Currencies Financial Markets News Finance Education Courses From an industry perspective, the move reflects a broader trend among Indian pharma leaders shifting from being exporters to becoming integrated US manufacturers. Compared to peers like Sun Pharmaceutical Industries Limited and Dr. Reddy's Laboratories, Aurobindo is positioning itself more aggressively to compete directly with global generic giants such as Viatris Inc. and Teva Pharmaceutical Industries in their core market. Company overview. Founded in 1986 and headquartered in Hyderabad, Aurobindo Pharma Limited is among India's largest pharmaceutical companies, manufacturing generic formulations and active pharmaceutical ingredients across more than 150 countries. The company has strong global presence across antibiotics, cardiovascular drugs, antiretrovirals, CNS therapies, and gastroenterology, supported by multiple USFDA-approved manufacturing facilities worldwide. The successful completion of the Lannett acquisition strengthens Aurobindo's long-term ambition of building a larger, vertically integrated pharmaceutical platform with stronger control over manufacturing, supply chains, and direct market access in the world's largest healthcare market. Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing. * Pranab Mohanty: Author Pranab is a financial analyst with experience in equities and financial modeling, with a strong understanding of data-driven analysis and quantitative techniques. He has written several analytical pieces and is deeply interested in market trends and valuation. Blending analytical thinking with financial insight, he explores strategies to better understand markets and support informed investment decisions.

Aurobindo Pharma diabetes drug wins USFDA approval, targets $514M market. HEALTHCAREBIOTECH Aurobindo Pharma has secured final USFDA approval for its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, manufactured by subsidiary APL Healthcare. This approval allows the company to market the drug in the US, tapping into an estimated market size of US$514 million. As an early applicant, Aurobindo is eligible for 180 days of shared generic drug exclusivity. Aurobindo Pharma has received final approval from the U.S. Food & Drug Administration (USFDA) for its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets. This paves the way for the company to enter a market estimated at US$514 million, based on data for the twelve months ending February 2026. Approval details. The company announced on April 7, 2026, that its wholly owned subsidiary, APL Healthcare Limited, received the final USFDA approval. The drug is bioequivalent to AstraZeneca's Xigduo XR tablets. Manufacturing will take place at APL Healthcare's Unit-IV facility. Aurobindo can now immediately begin manufacturing and marketing the medication in the U.S. As an early applicant for the Abbreviated New Drug Application (ANDA), Aurobindo is also eligible for 180 days of shared generic drug exclusivity, offering a key advantage in the competitive U.S. market. Strategic importance and market opportunity. This approval marks a significant step for Aurobindo Pharma, strengthening its presence in the U.S. generic drug market. The medication addresses Type 2 diabetes, a prevalent condition with substantial revenue potential indicated by the market size. The 180-day exclusivity period provides a vital window to capture market share before increased generic competition. This addition brings Aurobindo's total count of US FDA-approved products to 579. Company Track record. Aurobindo Pharma has a consistent history of securing USFDA approvals for its generic drug applications. The company prioritizes building its pipeline through R&D and strategic filings. Previously, Aurobindo has launched other diabetes medications in the U.S., such as Metformin Hydrochloride Extended-Release Tablets in 2012 and Saxagliptin Tablets in 2023. The company has also benefited from early ANDA submissions leading to exclusivity periods, as seen with Prasugrel Tablets. These past successes highlight Aurobindo's focus on expanding its therapeutic offerings in major regulated markets. Manufacturing and regulatory scrutiny. Despite this approval, Aurobindo Pharma has encountered recent US FDA scrutiny regarding its manufacturing facilities. In February 2026, an inspection of its Telangana formulation unit yielded 11 procedural observations. Following this, a Rajasthan subsidiary unit was classified as 'Official Action Indicated' (OAI) by the US FDA in March 2026. Earlier, in January 2026, its Hyderabad plant received a warning letter for issues concerning batch failure investigations. The company states these observations are procedural and do not expect immediate business impact, but ongoing attention to manufacturing standards remains critical for market access and compliance. Competitive landscape. Aurobindo competes with major Indian pharmaceutical firms such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Cipla, all possessing significant generic portfolios in the U.S. Dr. Reddy's launched its generic version of Kombiglyze XR in August 2023. Sun Pharma is developing specialty diabetes drugs and preparing for generic semaglutide launches. Cipla is also expanding its U.S. offerings with generics in diabetes and weight management. These competitors actively pursue market share with similar USFDA-approved generics, making timely launches and penetration vital. Market data. * The estimated market size for the product is US$514 million based on data for the twelve months ending February 2026. * Aurobindo Pharma has secured a total of 579 USFDA ANDA approvals as of March 31, 2026, comprising 554 final and 25 tentative approvals. Investor focus. * Monitor the official launch date and initial sales performance of the new diabetes medication in the U.S. * Observe how Aurobindo Pharma utilizes its 180-day exclusivity period to establish market presence. * Track the company's progress in resolving recent US FDA observations across its manufacturing facilities. * Analyze competitive landscape and market penetration against peer launches in the diabetes segment. * Watch for any further pipeline updates or new ANDA filings from Aurobindo Pharma. Disclaimer: This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication's editorial stance.

Aurobindo Pharma arm to acquire Khandelwal labs' non-oncology business for ₹325 cr. Aurobindo Pharma on Thursday announced that its subsidiary, Auro Pharma, will acquire the non-oncology prescription formulations business of Khandelwal Laboratories on a going concern basis through a slump sale. The acquisition will be carried out for a cash consideration of ₹325 crore, subject to customary true-up adjustments for working capital, as outlined in the definitive agreements, the company said in a regulatory filing, according to media reports. The business being acquired comprises 23 brands marketed across 67 stock-keeping units (SKUs), along with nine pipeline products. Anti-infective and pain management therapies form the core portfolios of the business. In FY25, the non-oncology prescription formulations business recorded a turnover of ₹113.5 crore and an EBITDA of ₹28.9 crore. It is supported by a field force of around 470 personnel and an extensive distribution network of over 1,600 stockists. Effective January 1, 2026, the acquisition is expected to strengthen Aurobindo Pharma's domestic formulations business by adding new brands in pain management and anti-infectives, complementing its existing product portfolio and expanding its presence in the Indian market.